Retroperitoneal fibrosis secondary to non-urology carcinomas: a clinical and outcome analysis of 97 cases
Sign Up to like & getrecommendations! Published in 2018 at "Clinical and Translational Oncology"
DOI: 10.1007/s12094-018-1936-y
Abstract: PurposeAccumulated evidences have reminded us that since the prognosis of retroperitoneal fibrosis (RPF) secondary to non-urology carcinoma is poor it is essential to distinguish this condition from others. The objective of this study is to… read more here.
Keywords: rpf; carcinoma; non urology; secondary non ... See more keywords
P806 Development of a clinical model to predict secondary non-response of anti-TNFα treatment on Crohn's disease
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjad212.0936
Abstract: Secondary non-response to anti-tumor necrosis factor-α (including Infliximab and Adalimumab) in patients with Crohn’s disease (CD) is common. Prediction of secondary non-response is essential for treatment decision for individual patients. The clinical model was constructed… read more here.
Keywords: response anti; model; non response; secondary non ... See more keywords
Clinical Efficacy of Alternative TNF Inhibitor and Secukinumab Between Primary Non-Responder and Secondary Non-Responder of Prior TNF Inhibitor in Ankylosing Spondylitis.
Sign Up to like & getrecommendations! Published in 2022 at "Modern rheumatology"
DOI: 10.1093/mr/roac005
Abstract: OBJECTIVE To compare the drug retention times and clinical efficacy of alternative tumor necrosis factor inhibitors (TNFi) and secukinumab in primary and secondary non-responders with ankylosing spondylitis (AS). METHODS AS patients treated with biologics and… read more here.
Keywords: non; secondary non; non responder; clinical efficacy ... See more keywords
Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab.
Sign Up to like & getrecommendations! Published in 2022 at "Rheumatology"
DOI: 10.1093/rheumatology/keac150
Abstract: OBJECTIVES Secondary inefficacy with infusion reactions and anti-drug antibodies (2NDNR) occurs in 14% of SLE patients receiving repeated rituximab courses. We evaluated baseline clinical characteristics, efficacy and safety of obinutuzumab, a next-generation humanised type-2 anti-CD20… read more here.
Keywords: non response; response rituximab; secondary non; sle patients ... See more keywords
P149 Evaluating outcomes for patients with systemic lupus erythematosus treated with obinutuzumab, a humanised anti-CD20 monoclonal antibody, following secondary non-depletion of B cells and non-response with rituximab
Sign Up to like & getrecommendations! Published in 2025 at "Rheumatology"
DOI: 10.1093/rheumatology/keaf142.189
Abstract: We looked at outcomes for nine SLE patients treated at University College London Hospitals (UCLH) with obinutuzumab, a humanised anti-CD20 mAb, between January 2020 and October 2023. Patients previously failed rituximab for intolerance and/or secondary… read more here.
Keywords: treatment; non depletion; anti cd20; none ... See more keywords
Hepatic Encephalopathy Secondary to Non-cirrhotic Portosystemic Shunt
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Investigative Medicine High Impact Case Reports"
DOI: 10.1177/23247096241258063
Abstract: Hepatic encephalopathy is uncommon in the absence of cirrhosis. We report a 71-year-old woman who presented with altered mental status in the setting of hyperammonemia for the second time in 6 months. Magnetic resonance imaging… read more here.
Keywords: hepatic encephalopathy; encephalopathy secondary; secondary non; portosystemic shunt ... See more keywords